MedTrace Logo

RMP-A03 Ocular Suspension in Patients With Pterygium

NCT05794204 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2024-12-06

No results posted yet for this study

Summary

The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.

Conditions

  • Pterygium

Interventions

DRUG

RMP-A03 - Dose 1

Patients will randomized to low dose of RMP-A03

DRUG

RMP-A03 - Dose 2

Patients will be randomized to high dose of RMP-A03

DRUG

RMP-A03 Placebo

Patients will be randomized to RMP-A03 Placebo

Sponsors & Collaborators

  • WuXi Clinical

    collaborator INDUSTRY

  • Suzhou Raymon Pharmaceuticals Company, Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-09
Primary Completion
2024-01-12
Completion
2024-01-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05794204 on ClinicalTrials.gov